Imipramine activates FAM3A-FOXA2-CPT2 pathway to ameliorate hepatic steatosis
{{output}}
Mitochondrial FAM3A has been revealed to be a viable target for treating diabetes and nonalcoholic fatty liver disease (NAFLD). However, its distinct mechanism in ameliorating hepatic steatosis remained unrevealed. High-throughput RNA sequencing revealed that ... ...